|Table of Contents|

Efficacy of third line treatment with arotinib in patients with extensive small cell lung cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2022 04
Page:
618-621
Research Field:
Publishing date:

Info

Title:
Efficacy of third line treatment with arotinib in patients with extensive small cell lung cancer
Author(s):
SHI Yangyang; LI Yanwen
Emergency Department，Shanghai Chest Hospital,Shanghai Jiao Tong University，Shanghai 200030，China.
Keywords:
anlotinib; third line treatment; small cell lung cancer
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2022.04.012
Abstract:
Objective:To evaluate the efficacy of third-line treatment with arotinib in patients with extensive small cell lung cancer.Methods:30 patients with extensive SCLC admitted to the emergency department in our hospital from October 2019 to October 2020 were randomly divided into the treatment group(15 cases treated with arotinib) and the observation group(15 cases without treatment).To evaluate the progression free survival(PFS),tumor markers,quality of life and adverse reactions.Results:The median PFS of the treatment group was 3.0 months,95% confidence interval(CI) was 2.4~3.6 months,the median PFS of the observation group was 1.0 months,95% confidence interval(CI) was 0.9~1.1 months,the data of the two groups were statistically significant(P＜0.05).The NSE of the treatment group before and after treatment were (89.93±24.54)ng/mL and (45.34±32.27）ng/mL,which was statistically significant before and after treatment(P＜0.05).The NSE of the observation group before and after treatment were (73.78±53.24)ng/mL and (86.72±70.40)ng/mL,there was no statistical significance before and after treatment(P＞0.05).PS score of treatment group before and after treatment was 1.20±0.68 and 1.40±0.51,there was no statistical significance before and after treatment(P＞0.05).The PS score of the observation group before and after treatment was 1.13±0.52 and 1.53±0.64,there was no statistical significance before and after treatment(P＞0.05).The common adverse reactions in the treatment group were hypertension,liver function damage,gastrointestinal reaction and fatigue.The common adverse reactions in the observation group were myelosuppression,gastrointestinal reaction,fatigue and rash.There was no significant difference between the two groups(P＞0.05).Conclusion:The efficacy of enrotinib in the third line treatment of extensive SCLC is clear,which can prolong the progression free survival,with acceptable adverse reactions and high safety.

References:

[1]曹毛毛,陈万青.GLOBOCAN 2020全球癌症统计数据解读［J］.中国医学前沿杂志（电子版）,2021,13(3):63-69. CAO MM,CHEN WQ.Interpretation of global cancer statistics in GLOBOCAN 2020 ［J］.Chinese Journal of Frontier Medicine(Electronic Edition),2021,13(3):63-69.
[2]SALTOS A,SHAFIQUE M,CHIAPPORI A.Update on the biology,management,and treatment of small cell lung cancer(SCLC)［J］.Front Oncol,2020,10:1074.
[3]常智.小细胞肺癌药物治疗进展研究［J］.吉林医学,2020,41(2):415-417. CHANG Z.The progress of drug therapy for small cell lung cancer ［J］.Jilin Medicine,2020,41(2):415-417.
[4]SHEN G,ZHENG F,REN D,et al.Anlotinib:a novel multi-targeting tyrosine kinase inhibitor in clinical development ［J］.J Hematol Oncol,2018,11(1):120.
[5]罗详冲.安罗替尼治疗肺癌的临床研究进展［J］.中国肿瘤生物治疗杂志,2019,26(6):710-714. LUO XC.Clinical research progress of arotinib in the treatment of lung cancer ［J］.Chinese Journal of Tumor Biotherapy,2019,26(6):710-714.
[6]TANIGUCHI H,SEN T,RUDIN CM.Targeted therapies and biomarkers in small cell lung cancer［J］.Front Oncol,2020,10:741.
[7]李春国,刘伟.小细胞肺癌患者临床治疗进展研究［J］.中外医学研究,2012,10(3):160-161. LI CG,LIU W.Progress in clinical treatment of patients with small cell lung cancer ［J］.Chinese and Foreign Medical Research,2012,10(3):160-161.
[8]HANAHAN D.Rethinking the war on cancer ［J］.Lancet,2014,383(9916):558-563.
[9]LI H,LIU Y,LIU X,et al.A novel multi-target tyrosine kinase inhibitor anlotinib combined with irinotecan has in-vitro anti-tumor activity against human small-cell lung cancer ［J］.Anticancer Drugs,2020,31(10):1057-1064.
[10]罗详冲,刘晶晶,李高峰.安罗替尼治疗晚期恶性肿瘤的研究进展［J］.肿瘤,2019,39(12):1025-1030. LUO XC,LIU JJ,LI GF.Research progress of anlotinib in the treatment of advanced malignant tumor ［J］.Tumor,2019,39(12):1025-1030.
[11]刘晓文.安罗替尼三线治疗广泛期小细胞肺癌的疗效评价［J］.中国现代药物应用,2021,15(1):154-156. LIU XW.Evaluation of the therapeutic effect of allotinib in the treatment of extensive small cell lung cancer ［J］.Modern Chinese Medicine Application,2021,15(1):154-156.
[12]王微,王建华,叶军辉,等.安罗替尼联合替吉奥胶囊治疗复发性或难治性小细胞肺癌的近期疗效及安全性［J］.浙江医学,2019,41(23):2536-2539. WANG W,WANG JH,YE JH,et al.The short-term efficacy and safety of combination of anlotinib and tegafur capsule in the treatment of recurrent or refractory small cell lung cancer ［J］.Zhejiang Medical Journal,2019,41(23):2536-2539.
[13]袁亮,侯新丽.安罗替尼在小细胞肺癌(SCLC)三线及以上治疗中的疗效及安全性［J］.现代肿瘤医学,2020,28(21):3710-3714. YUAN L,HOU XL.Efficacy and safety of arotinib in the treatment of small cell lung cancer ［J］.Modern Oncology,2020,28(21):3710-3714.
[14]CHENG Y,WANG Q,LI K,et al.OA13.03 Anlotinib as third-line or further-line treatment in relapsed SCLC:A multicentre,randomized,double-blind phase 2 trial［J］.Journal of Thoracic Oncology:Official Publication of the International Association for the Study of Lung Cancer,2018,13(10):351-352.
[15]中国医师协会肿瘤医师分会,中国医疗保健国际交流促进会肿瘤内科分会.Ⅳ期原发性肺癌中国治疗指南(2021年版)［J］.中华肿瘤杂志,2021,43(1):39-59. Cancer Physicians Branch of Chinese Medical Association,Cancer Internal Medicine Branch of China Association for International Exchange of Medical Care.Chinese guidelines for the treatment of primary lung cancer(2021 Edition) ［J］.Chinese Journal of Oncology,2021,43(1):39-59.
[16]文文,肖超,冯青青,等.安罗替尼三线治疗广泛期小细胞肺癌的效果［J］.青岛大学学报（医学版）,2020,56(6):727-729. WEN W,XIAO C,FENG QQ,et al.Effect of third-line treatment with arotinib on extensive stage small cell lung cancer ［J］.Journal of Qingdao University(Medical Edition),2020,56(6):727-729.
[17]王静怡,董量,付浩宇,等.安罗替尼二三线治疗的广泛期小细胞肺癌患者预后分析［J］.中国临床医生杂志,2021,49(1):38-41. WANG JY,DONG L,FU HY,et al.Analysis of prognosis of patients with extensive stage small cell lung cancer treated with second-line and third-line treatment with anlotinib ［J］.Chinese Journal of Clinicians,2021,49(1):38-41.

Memo

Memo:
-
Last Update: 1900-01-01